Bertold Bar-Bouyssière

Dentons (Brussels)
Lawyer (Partner)

Dr. Bertold Bär-Bouyssière is one of the leading practitioners of competition law in Brussels and Germany, with close to 20 years of experience. He serves corporate clients around the world in complex competition law matters, with a focus on the life science, technology and financial services sectors. Bertold advises at the forefront of competition law developments. He currently represents clients in the EU’s and OFT’s first ever investigations into "reverse patent settlements" in the pharmaceutical sector. Bertold also regularly represents clients in merger control proceedings. In 2013, Bertold’s team was nominated for "Belgian Competition Team of the Year" and received a "Special Mentioning" in the Belgian Legal Award Procedure. A Fulbright alumni, Bertold is a German qualified lawyer but also admitted to the New York and Brussels bars. Before joining DLA Piper in October 2005, Bertold was a partner in the Brussels office of Coudert Brothers. Bertold advises in all areas of EU, German and Belgian competition law, including merger control, horizontal and vertical restraints, investigations and State. He has extensive experience in the application of competition rules in a large variety of industry sectors including chemicals, crop protection, petrochemicals, pharmaceuticals, medical devices, gas, electricity, steel, motor vehicles, automotive components, construction equipment, cable television & multimedia, telecommunications, aerospace, satellite launching, tourism, air transport, defence equipment, online gaming, shipbuilding, food processing, fuel card services, financial services and luxury watches.


Linked authors

Dentons (Warsaw)
Dentons (Warsaw)
Dentons (Brussels)
Dentons (Washington)
Dentons (Milan) (Studio Legale Tributario)


4778 Bulletin

Bertold Bar-Bouyssière, Alina Lacatus, Jacob Borum, Darach Connolly The EU Commission invites comments from all interested parties on commitments offered by pharmaceutical company to address the Commission’s concerns over excessive pricing (Aspen)


Aspen: Quick Fix But Missed Opportunity* What are commitments? The recent effort by the Commission to settle the Aspen case suggests that commitment decisions are the preferred route to settle complex excessive pricing cases at EU-level. Previous commitment cases where high prices have been (...)

Bertold Bar-Bouyssière, Catherine Derenne Pharma and Mergers: An overview of EU and national case law


Merger control in the pharmaceutical sector follows the normal pattern of merger analysis, taking account of sectoral specificities. Mergers (used here as a shortcut for all transactions subject to merger control) can involve different types of actors, e.g. manufacturers of branded drugs (’innovators’ or ’originators’), manufacturers of generic drugs, manufacturers of biosimilars, non-manufacturing inventors, universities or start-ups, different categories of wholesalers and distributors, retailers (pharmacies), hospitals, even global investment banks, and the drugs in question can be intended for human or veterinary use. There are also mergers involving manufacturers or distributors of medical equipment, other medical products, or chemicals for use in medicinal products.


Send a message